T. Rowe Price Health Sciences Fund, Inc.
T. ROWE PRICE HEALTH SCIENCES FUND, INC. · Series S000002088 · 2 share classes
data updated 2026-09-08
Fund profile
As filed in the prospectus · 2026 Q1
The fund seeks long-term capital appreciation.
The fund invests at least 80% of assets in common stocks of health sciences companies—pharmaceutical firms, biotechnology companies, medical device makers, and health care services providers—using fundamental bottom-up analysis to identify high-quality growth companies or, when valuations appear elevated, undervalued opportunities. The fund may also hold foreign stocks and recently public or privately held companies. Because the fund's allocation among the four health sciences areas varies with the adviser's outlook, its sector exposure will shift over time.
| Share class | Expense ratio | As of |
|---|---|---|
| PRHSX | 0.80% | 2025 Q1 |
| THISX | 0.67% | 2025 Q1 |
Portfolio turnover 61.60% · as of 2026 Q1
Allocation
Asset groups · long / short shown separately, never netted · 2026 Q2
| Stocks | 99.36% |
| Cash & short-term | 0.65% |
| Bonds | 0.15% |
Latest quarter
What changed since the fund's previous filing
Return profile
Total return as filed — price change plus distributions reinvested · trailing figures to Apr 2026
| Share class | 1-year | 3-year | 5-year | Vol | Worst fall |
|---|---|---|---|---|---|
| +12.27% | +16.32% | +11.89% | 16.65% | -18.45% | |
| +12.43% | +16.79% | +12.59% | 16.65% | -18.36% |
These classes hold the same portfolio, so the 0.70pp spread over 5 years is the cost difference between them — roughly 0.14pp a year — not a difference in what they own.
May 2026 and Jun 2026 have been filed since the trailing figures were struck, so they are not in the table above or the curve — every figure here shares one cut-off, which is what makes them comparable with other funds.
Debt profile
What this fund holds — value-weighted across its bond and securitized long positions · as of 2026-06-30
Share of the fund's debt by how its coupon behaves — the fact that decides whether a rate move reaches this portfolio at all.
| Fixed rate | 81.1% |
| Zero-coupon or unclassified | 18.9% |
Share of the fund's debt value in each maturity band, shortest first.
| <1y | 26.3% |
| 3-5y | 73.7% |
Based on what filers reported; a filer that never reported a flag also reads as none.
Risk profile
Interest-rate and credit-spread sensitivity, both in years · as of 2026Q2
This fund filed the credit-spread disclosure and reported no sensitivity — measured, and the answer is none.
Show the numbers
| Tenor | Rate yrs | IG yrs | HY yrs | IG $/bp | HY $/bp |
|---|---|---|---|---|---|
| 3 mo | +0.00 | +0.00 | +0.00 | $0 | $0 |
| 1 yr | +0.00 | +0.00 | +0.00 | $0 | $0 |
| 5 yr | +0.00 | +0.00 | +0.00 | $0 | $0 |
| 10 yr | +0.00 | +0.00 | +0.00 | $0 | $0 |
| 30 yr | +0.00 | +0.00 | +0.00 | $0 | $0 |
Dollar change per 1bp of spread movement, as filed and sign-anchored. A blank cell was not filed; a zero was.
Holdings
By % of NAV · equity positions carry filed share counts · every resolvable issuer links to its company page
| Ticker | Issuer | %NAV | Reported price | Value | Shares |
|---|---|---|---|---|---|
| LLY | ELI LILLY & COLLY | 14.28% | $1,199.43 | $1.71B | 1.4M |
| JNJ | JOHNSON & JOHNSONJNJ | 6.63% | $253.97 | $792.01M | 3.1M |
| UNH | UNITEDHEALTH GROUP INCUNH | 5.99% | $415.63 | $715.61M | 1.7M |
| ABBV | ABBVIE INCABBV | 5.10% | $251.64 | $609.30M | 2.4M |
| MRK | MERCK & CO. INC.MRK | 4.01% | $128.50 | $478.73M | 3.7M |
| GILD | GILEAD SCIENCES INCGILD | 2.82% | $126.34 | $336.99M | 2.7M |
| TMO | THERMO FISHER SCIENTIFIC INCTMO | 2.52% | $501.36 | $301.21M | 600.8K |
| VRTX | VERTEX PHARMACEUTICALS INCVRTX | 2.28% | $496.73 | $272.28M | 548.1K |
| BMY | BRISTOL-MYERS SQUIBB COBMY | 2.11% | $57.62 | $251.85M | 4.4M |
| ABT | ABBOTT LABORATORIESABT | 1.89% | $90.74 | $225.34M | 2.5M |
Reported price is the fund's own reported value divided by its own reported shares at 2026-06-30 — not a live quote, and not what the fund paid.
Top 10 positions are 47.62% of net assets, top 25 65.98%, across 279 issuers.
See more of this fund's book
More positions with filed share counts, and the quarter-over-quarter change list rather than the largest few — free with an account, no card required.
Sign in free